Benefits

We found one RCT. Nineteen patients with more than four attacks of EM per year were enrolled in a 6-month double-blind, placebo-controlled trial of aciclovir, 400 mg twice daily. There were no attacks in the aciclovir group (range 0-2), compared with a median of three (1-6) in the placebo group (P<0-0005). At the time of inclusion, five patients had no clinical evidence of disease precipitation by HSV; two of them were in the aciclovir group; one showed complete disease suppression.6

We found another RCT, which showed that topical aciclovir therapy used in a prophylactic manner is not successful in preventing recurrent herpes-associated EM.7

0 0

Post a comment